Canbridge Pharmaceuticals (HKSE:01228) ROCE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01228 Canbridge Pharmaceuticals Inc HKSE:01228
48 GF Score
Price HK$2.05
GF Value HK$0.38
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Canbridge Pharmaceuticals ROCE %?

Canbridge Pharmaceuticals HKSE:01228 +2.50% 48 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:01228 with a GF Score™ of 48/100 and a GF Value™ of HK$0.38 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Canbridge Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Canbridge Pharmaceuticals  (HKSE:01228) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Canbridge Pharmaceuticals ROCE % Related Terms

Canbridge Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Canbridge Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Canbridge Pharmaceuticals ROCE % Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -183.62 -79.51 -147.88 0.00 0.00

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -204.17 0.00 0.00 0.00 0.00
HKSE:01228
48GF Score
Canbridge Pharmaceuticals Inc HKSE:01228
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Canbridge Pharmaceuticals ROCE % Calculation

Canbridge Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=18.833/( ( (124.718 - 515.269) + (182.712 - 503.027) )/ 2 )
=18.833/( (-390.551+-320.315)/ 2 )
=18.833/-355.433
=-5.30 %

Canbridge Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-97.126/( ( (115.32 - 553.263) + (182.712 - 503.027) )/ 2 )
=-97.126/( ( -437.943 + -320.315 )/ 2 )
=-97.126/-379.129
=0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Canbridge Pharmaceuticals (HKSE:01228) has a ROCE % of 0.00% as of Dec. 2025.
Is Canbridge Pharmaceuticals' ROCE % too high?
Canbridge Pharmaceuticals' current ROCE % is 0.00%. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' ROCE % compare to VRTX and REGN?
Canbridge Pharmaceuticals' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Canbridge Pharmaceuticals's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals (HKSE:01228) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.38, compared to a current price of HK$2.05 — trading 439.5% above its estimated fair value. The current ROCE % is 0.00%. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Canbridge Pharmaceuticals (HKSE:01228), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Canbridge Pharmaceuticals (HKSE:01228) Overvalued in 2026?

Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued. The current stock price of HK$2.05 is trading 439.5% above its estimated GF Value™ of HK$0.38. GuruFocus considers Canbridge Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for HKSE:01228:

  • ROCE %: 0.00%
  • GF Value™: HK$0.38 vs. price of HK$2.05 (439.5% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the HKSE:01228 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canbridge Pharmaceuticals Business Description

Address No. 388 Xinping Street, Unit 9, 10th Floor, Building 21, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score

Get the complete analysis for HKSE:01228

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.05
Price
HK$0.38
GF Value